Meanwhile, high levels of GLUT3 in glioblastomas selectively mediate glucose uptake, indicating that it confers a substantial growth-competitive advantage to cancer cells, which may provide a potential therapeutic window for targeting GLUT3 to reduce the production of lactate caused by glycolysis [107]. The gene discussed is SLC2A3; the disease is glioblastoma.